Skip to main content
. 2019 Nov 15;98(46):e17921. doi: 10.1097/MD.0000000000017921

Figure 2.

Figure 2

Pathology and immunohistochemistry of ACTs. (A) HE strain of adrenocortical tumors (×100). (B) Vimentin strong staining (cytoplasm) (×100). (C) Negative of chromogranin A (×100). (D) Negative of S100 (×100). (E) Positive of synaptophysin in ACT (cytoplasm) (×100). (F) CK strong staining (nucleus and cytoplasm) (×100). (G). Type 2 3βHSD moderate staining (×100). (H) P45017α weak staining in ACT (×100). (I) P53 stain in nucleus of ACT, (×100). (J) p21 stain in nucleus of ACT (×100). (K). p27 stain in nucleus and cytoplasm of ACT (×100). (L). Cyclin D1 in part nucleus and cytoplasm of ACT (×100). (M). Ki-67 stain (nucleus) in ACT (×100). (N). IGF-2 moderate staining in part cells (nucleus and cytoplasm) of ACT (×100). (O). β-catenin nuclear staining in ACTs (×100).